Latest Headlines

Follow companies to personalize your feed

Today

Amaero Ltd

Results of First Court Hearing

in an hour

Geiger Counter Limited

Subscription Rights Rump Placing

an hour ago

Awfis Space Solutions Limited

Press Release May 07 2026

2 hours ago

Aker Bp Asa

Aker BP: First Quarter 2026 Results

2 hours ago

Carnival Plc

Cancellation - Carnival Plc

2 hours ago

Molten Ventures Plc

Release of Monthly Portfolio Update Newsletter

2 hours ago

Bango Plc

LinkedIn partners with the DVM from Bango

2 hours ago

Archies Limited

Press Release May 07 2026

2 hours ago

Blencowe Resources Plc

Rocket Component Testing Programme

3 hours ago

Stora Enso Oyj A

Stora Enso Interim Report January-March 2026: Focus on our own actions drives results

3 hours ago

Bae Systems Plc

BAE Systems – Trading update

3 hours ago

Aberdeen Group Plc

Agreement With Herald Investment Trust and Saba

3 hours ago

Shell Plc

Shell plc First Quarter 2026 Interim Dividend

3 hours ago

Schroders Capital Global Innovation Trust Plc - Inov

Publication of a Tender Offer Circular

3 hours ago

Coiled Therapeutics Plc

Attendance at Endless Frontier Labs 2026

3 hours ago

Herald Investment Trust

Secured Future for Herald

3 hours ago

Bluefield Solar Income Fund

Completion of £120m financing for solar portfolio

3 hours ago

Octopus Renewables Infra Trust

Q1 2026 Dividend Declaration

3 hours ago

Essensys Plc

Day 58 Acceptance Level Update

3 hours ago

Oryx International Growth Fund

Weekly Net Asset Value Reporting

3 hours ago

Jun 17 2021

5 min read

Press Release Jun 17 2021

Name: 6ix Investment Platform
Brand: 6ix

Lupin Limited has informed the Exchange regarding a press release dated Jun 17, 2021, titled "Lupin Receives U.S. FDA Approval for Sevelamer Hydrochloride Tablets".

View Attachment